In a prior study of patients following TSC CPC, it was found that the reduction in IOP depends on the decrease in the level of the inflammatory biomarker ICAM-1 in the peripheral blood, against the background of long-term (3 months) local non-steroidal anti-inflammatory therapy with ketorolac [28]. The gene discussed is ICAM1; the disease is tuberous sclerosis.